Drug treatment of multiple sclerosisPOLMAN, C. H; UITDEHAAG, B. M. J.BMJ. British medical journal (International ed.). 2000, Vol 321, Num 7259, pp 490-494, issn 0959-8146Article

The value of continuous intra-operative EEG monitoring during carotid endarterectomyVAN ALPHEN, H. A. M; POLMAN, C. H.Acta neurochirurgica. 1988, Vol 91, Num 3-4, pp 95-99, issn 0001-6268Article

Multiple sclerosis : some possible therapeutic opportunitiesDIJKSTRA, C. D; POLMAN, C. H; BERKENBOSCH, F et al.Trends in pharmacological sciences (Regular ed.). 1993, Vol 14, Num 4, pp 124-129, issn 0165-6147Article

Carotid endarterectomy: how does it work? a clinical and angiographic evaluationVAN ALPHEN, H. A. M; POLMAN, C. H.Stroke (1970). 1986, Vol 17, Num 6, pp 1251-1253, issn 0039-2499Article

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisoloneHOOGERVORST, E. L. J; POLMAN, C. H; BARKHOF, F et al.Multiple sclerosis. 2002, Vol 8, Num 5, pp 415-419, issn 1352-4585Article

Long-term follow-up of suspected though unconfirmed MSNIELSEN, J. M; UITDEHAAG, B. M. J; POLMAN, C. H et al.Multiple sclerosis. 2008, Vol 14, Num 7, pp 985-987, issn 1352-4585, 3 p.Article

Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosisPOLMAN, C. H; KOETSIER, J. C; WOLTERS, E. P et al.Clinical neurology and neurosurgery. 1985, Vol 87, Num 3, pp 187-192, issn 0303-8467Article

Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease progressionTEUNISSEN, C. E; SOMBEKKE, M; WINSEN, L. Van et al.Multiple sclerosis. 2012, Vol 18, Num 8, pp 1092-1098, issn 1352-4585, 7 p.Article

Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?KRAGT, J. J; NIELSEN, J. M; VAN DER LINDEN, Fah et al.Multiple sclerosis. 2011, Vol 17, Num 2, pp 234-240, issn 1352-4585, 7 p.Article

Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosisSOMBEKKE, M. H; DER VOORT, Lf Van; POLMAN, C. H et al.Multiple sclerosis. 2011, Vol 17, Num 8, pp 922-930, issn 1352-4585, 9 p.Article

Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiencyWORTHINGTON, V; KILLESTEIN, J; EIKELENBOOM, M. J et al.Neurology. 2010, Vol 75, Num 18, pp 1617-1622, issn 0028-3878, 6 p.Article

Association between MRI parameters and the MS severity scale: a 12 year follow-up studyMINNEBOO, A; UITDEHAAG, Bmj; JONGEN, P et al.Multiple sclerosis. 2009, Vol 15, Num 5, pp 632-637, issn 1352-4585, 6 p.Article

Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?KORTEWEG, T; ROVARIS, M; NEACSU, V et al.Multiple sclerosis. 2009, Vol 15, Num 4, pp 465-471, issn 1352-4585, 7 p.Article

Predicting short-term disability progression in early multiple sclerosis : added value of MRI parametersMINNEBOO, A; JASPERSE, B; BARKHOF, F et al.Journal of neurology, neurosurgery and psychiatry. 2008, Vol 79, Num 8, pp 917-923, issn 0022-3050, 7 p.Article

Responsiveness and predictive value of EDSS and MSFC in primary progressive MSKRAGT, J. J; THOMPSON, A. J; MONTALBAN, X et al.Neurology. 2008, Vol 70, Num 13, pp 1084-1091, issn 0028-3878, 8 p., 2Article

Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? relation to disability and MRIKALKERS, N. F; STRIJERS, R. L. M; JASPERSE, M. M. S et al.Clinical neurophysiology. 2007, Vol 118, Num 6, pp 1332-1340, issn 1388-2457, 9 p.Article

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. CommentaryPOLMAN, C. H; KILLESTEIN, J; RAUER, S et al.Journal of neurology, neurosurgery and psychiatry. 2006, Vol 77, Num 6, issn 0022-3050, 712,739-742 [5 p.]Article

Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoireVAN NOORT, J. M; VERBEEK, R; MEILOF, J. F et al.Multiple sclerosis. 2006, Vol 12, Num 3, pp 287-293, issn 1352-4585, 7 p.Article

Normal- appearing white matter changes vary with distance to lesions in multiple sclerosisVRENKEN, H; GEURTS, J. J. G; KNOL, D. L et al.American journal of neuroradiology. 2006, Vol 27, Num 9, pp 2005-2011, issn 0195-6108, 7 p.Article

Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosisEIKELENBOOM, M. J; KILLESTEIN, J; UITDEHAAE, B. M et al.Multiple sclerosis. 2005, Vol 11, Num 5, pp 520-523, issn 1352-4585, 4 p.Article

Value of health-related quality of life to predict disability course in multiple sclerosisVISSCHEDIJK, M. A. J; UITDEHAAG, B. M. J; KLEIN, M et al.Neurology. 2004, Vol 63, Num 11, pp 2046-2050, issn 0028-3878, 5 p.Article

αB-Crystallin genotype has impact on the multiple sclerosis phenotypeVAN VEEN, T; VAN WINSEN, L; CRUSIUS, J. B. A et al.Neurology. 2003, Vol 61, Num 9, pp 1245-1249, issn 0028-3878, 5 p.Article

Safety, tolerability, and efficacy of orally administered cannabinoids in MSKILLESTEIN, J; HOOGERVORST, E. L. J; REIF, M et al.Neurology. 2002, Vol 58, Num 9, pp 1404-1407, issn 0028-3878, SUP6Article

The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MSBREX, P. A; MOLYNEUX, P. D; POLMAN, C. H et al.Neurology. 2001, Vol 57, Num 12, pp 2185-2190, issn 0028-3878Article

Association of interleukin-1β and interleukin-1 receptor antagonist genes with disease severity in MSSCHRIJVER, H. M; CRUSIUS, J. B. A; UITDEHAAG, B. M. J et al.Neurology. 1999, Vol 52, Num 3, pp 595-599, issn 0028-3878Article